Dr. Georg Nebgen von Klitzing

Profile

Dr. Georg Nebgen von Klitzing, is Chairman & CEO of Longea AG and Vivant Holdings LLC. He has 25+ years of US and European private equity investment and operational industry expertise in healthcare. Previously he was Co-Founder & Managing General Partner of NGN Capital in New York. Prior to this he held positions as Principal at MPM Capital in Boston and Managing Director of MPM Capital GmbH. Before this he was with Schering-Plough Corporation, as Managed Care Area Manager for New England and as Business Unit Head, Oncology & Biotech and Business Unit Head, Cardiovascular & CNS in its Swiss subsidiary. At F. Hoffmann-La Roche, he led as Technical Project Leader the global research & development team for Invirase/Fortovase to its NDA filing and FDA approval.

Dr. Nebgen von Klitzing’s background comprises numerous private equity investments, IPO’s,  follow-on offerings, corporate spin-outs and exit transactions across a broad spectrum in healthcare. He has extensive experience on public and private boards. He was Chairman of  Exosome Diagnostics acquired by Bio-Techne, served on the Board of Directors of ACT Biotech, Artisan Pharma, acquired by Asahi Kasei Pharma, Kourion, acquired by Viacell, Javelin Pharmaceuticals, sold to Hospira, KIKA Medical, acquired by Merge Healthcare, Omrix, exited to Johnson & Johnson, Santhera Pharmaceuticals AG, Swiss IPO and Valtech Cardio acquired by Edwards. He served as the President of the German-American Business Council in Boston.

He obtained his Ph.D. in Pharmaceutical Technology Sciences from the University of Bonn, Germany and his executive MBA from the University of St. Gallen, Switzerland.

Dr. Nebgen von Klitzing is a Member of the Board of Experts of THE HEALTH CAPTAINS CLUB.